on FSD Pharma Inc.
FSD Pharma Receives Institutional Review Board Approval for Unbuzzd(TM) Study
FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A), a biopharmaceutical company, has received institutional review board (IRB) approval for its METAL-2 trial in the USA. This marks a significant step forward, enabling the company to recruit participants and plan the clinical study on Unbuzzd(TM) for acute alcohol intoxication.
Dr. Andrzej Chruscinski, Vice-President of Clinical and Scientific Affairs, expressed enthusiasm about advancing the clinical research. This approval allows FSD Pharma to explore innovative solutions in the field of alcohol misuse.
FSD Pharma focuses on developing assets and biotech solutions for neurodegenerative and metabolic disorders, along with alcohol misuse treatments. The company retains ownership stakes and royalty rights in various subsidiaries and is committed to ongoing research and development.
R. H.Copyright © 2024 FinanzWire, all reproduction and representation rights reserved. Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all FSD Pharma Inc. news